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1 year 3 years 5 years
Group 1 91%(4) 86%(5) 83%(6)
Group 2 86%(9) 86%(9) 86%(9)
Group 3 87%(9) 73%(12) 73%(12)
Group 4 63%(11) 46%(12) 38%(12)
Year Total # of units destroyed
2011 112
2012 35
2013* 127
*Through 10/9/2013
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chemotherapy (CT) we divided the pt in the following
groups: 1) 64 pt in 1st complete remission (CR) after 1 CT
line, all with IPI2; 2) 15 pt in 1st CR after 2 CT lines; 3) 15
pt in 2nd CR; 4) 19 pt with more advanced diseased. Ritux-
imab (R) was used with CT in 78 pt before SCT. The 1st line
CT most frequently used was: R-CHOP: 71 pt (63%); CHOP:
28 pt (25%).
Conditioning regimen was: 93 pt BEAM and 20 pt
FEAM. Hematopoietic stem cells were collected from:
peripheral blood (PB) in 100, bone marrow (BM) in 2, and
PB+BM in 11 pt.
The cause of death was: relapse/progression - 17 pt; non-
relapsed mortality e 8 pt and secondary neoplasia 1pt.
The median follow up of alive pt was 34 months (1-221).
Overall survival (OS) at 1, 3 and 5 years was 85%(3);
75%(4); 73%(5). DFS at 1, 3 and 5 years was 84%(4);
80%(4); 75%(5) respectively.
There were signiﬁcant differences in OS between the 4
groups considered e table 2 (p<0.01). In univariate anal-
ysis OS was signiﬁcantly better if: early stage at diagnosis,
less than 2 CT lines before SCT, disease status before SCT in
CR, ﬁrst line CT with R-CHOP, PB stem cells.
Conclusion: About 70 % of high-risk pt were free of disease
after conventional CT followed by SCT. The outcome is
inﬂuenced by disease status at SCT. Despite our results don’t
allow direct comparison of the impact of immunoCT with R,
our pt in the R group had a better outcome.Most studies with
SCT consolidation in these pt were performed in the pre-R
era. There is as need to redeﬁne the role of this treatment
strategy nowadays. Further knowledge of prognosis factors is
necessary, especially in young pt with high-risk disease at 1st
CR, to determine whether the SCT still improves outcome.BMT ADMINISTRATORS/QUALITY157
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Background/Objective: 126 patients were identiﬁed as be-
ing deceased with over 350 stem cell units in storage. The
inability to dispose of these cells has a signiﬁcant impact on
our program; primarily freezer space availability.
The process of obtaining required documentation for the
disposal of cells had not been streamlined, and no one had
oversight for the process, resulting in a lack of documenta-
tion needed to dispose of cells.
Methods: In June of 2012, a data manager took ownership of
the project. In July of 2012, the Cellular Therapeutics
Department Cell Destruction Policy was revised to include
the SSDI report as valid documentation necessary for
destruction of cells and the new process was implemented.Per programmatic policy, appropriate documentation is
requested as soon as possible after notiﬁcation of a re-
cipient’s death. Aggressive attempts are made to obtain
EITHER:
A death certiﬁcate
OR An SSDI report
If any information is inconsistent, additional corrobo-
rating documentation is still necessary to corroborate patient
identiﬁcation. These documents are scanned and stored on a
(secure) shared drive.
The Cellular Therapeutics (CT) Team then reviews docu-
mentation submitted by the data management team.
Appropriate forms are ﬁlled out by CT and the documenta-
tion is veriﬁed by a second CT Team member. Forms must
then be signed by either the Processing Facility Medical Di-
rector or the recipient’s physician per FACT Guidelines (D
11.1.4). The Product disposal may then occur per policy.
Results: Our freezer capacity is 3660 total units (11 freezers
of different sizes). 2627 Autologous Units and 705 Allogeneic
Units ¼ 3332 total units are currently stored (10/1/
13). With ownership of the new streamlined process,
documentation has been received on an additional 52 pa-
tients (150 units) are now eligible for destruction, and
documentation is pending on an additional 37 patients (104
units). 2013 data represents a 72% increase in cells eligible for
destruction over 2012.158
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Abstract/Background: The prevention of hospital acquired
infections is an ongoing performance improvement oppor-
tunity in our hematopoietic stem cell transplant (HSCT)
population. An outbreak of Vancomycin-Resistant Entero-
cocci (VRE) occurred in late 2011 that extended through
2012. A multidisciplinary approach to impact VRE has
resulted in major improvement and sustained reduction in
VRE rates in 2013.
Objective/Methods:
1. Multidisciplinary Integration
In order to achieve the goal of preventing Hospital
Acquired Infections our program works closely with
the hospital Infection Prevention (IP) team. The IP
team attends/reports unit data and opportunities to:
HSCT Quality Management Meeting (ad hoc)
 Sarah Cannon Blood Cancer Network Infection Pre-
vention Team and Quality Calls
 Both the HSCT and the IP team participate in
monthly IP Multidisciplinary Rounding
 IP performs consultative review of IP speciﬁc HSCT
Policies and Procedures
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house wide IP Committee meetings
2. IP and HSCT Quality Manager Performed an IRB
Approved Study “Housekeeping Education on VRE
Rates and Patient Satisfaction on a Bone Marrow
Transplant Unit”
 Housekeeping and Biomedical Engineering Staff
were in-serviced by the Medical director of the HSCT
program and the Infectious Disease Consulting
Physician on the importance of environmental
cleanliness in the transplant patient population.
 Cleaning of the patient environment was observed
and efﬁcacy of the cleaning reported in real-time
with 3M Clean-Trace NG Luminometer.
 Rates of VRE colonization and HCAHPS scores for
Cleanliness on the BMT unit were collected,
analyzed and reported.
3. Ongoing integration of Housekeeping and HSCT
Nursing Leadership rounding and audits
4. Revised In-Patient Visiting Restrictions
 The IP team provided supporting data that visitors
14 years of age and over can follow basic pre-
cautions, infection control measures, don PPE
appropriately.
 All visitors are screened for illness prior to entry on
the HSCT units. If the individual is free of any signs/
symptoms of illness they are provided a dated
“guest” sticker and allowed entry into the unit. This
process is repeated daily.
Results/Conclusions: Consistent multidisciplinary engage-
ment and vigilance have reduced VRE rates on the in-patient
HSCT unit.159
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Background: In 2012, ASBMT published revised guidelines
for Hematopoietic Stem Cell Transplant (HSCT) physician
training using the AGCME framework of core competencies:
1. Medical Knowledge
2. Patient Care
3. Interpersonal and Communication Skills
4. Practice-Based Learning and Improvement
5. Systems-Based Practice
6. ProfessionalismThe Sarah Cannon Blood Cancer Network (SCBCN) con-
sists of 5 programs in the US performing over 850 HSCT
annually. Many HSCT programs currently rely on documen-
tation by the Medical Director to assure compliance with
training standards and FACT accreditation. Without a formal
plan for prospective evaluation of core competencies, there is
a risk that such evaluations may be subjective or incomplete.
A Sarah Cannon team reviewed the guidelines and proposed
creation of a physician training documentation tool that
would meet the intent of ASBMT training guidelines and
relevant FACT standards for documentation of physician
training as well as provide guidance related to quality ac-
tivity learning options.
Methods: As part of the physician led SCBCN quality pro-
gram, a documentation tool was developed to assure
compliance with the revised guidelines for fellows in
training in the SCBCN and for recent graduates of fellowship
programswho joined the SCBCN as attending physicians. The
tool was developed in a check list format that detailed the
ASBMT training objectives, the SCBCN learning options, as
well as assessment of methods and validation. Using the
2012 American Society of Blood andMarrow Transplantation
Guidelines for Training in Hematopoietic Progenitor Cell
Transplantation and the FACT standards relating to docu-
mentation of physician training, the tool is designed to pro-
vide required documentation and offer opportunities for
quality activity-based learning options. A primary goal of this
project is to create meaningful learning opportunities for the
trainee and provide value to the transplant program.
Particular attention was given to core competencies 3, 4, & 5
in connecting quality activities to demonstrate competence.
The tool was reviewed and adopted by SCBCN transplant
physicians.
We are presently evaluating the tool with physicians who
have recently joined SCBCN and their assigned mentors.
Discussion: The following measures will be assessed at
the end of the pilot period:
1. Ease of use of the tool
2. Overall Value of Quality Learning Options for Trainee
3. Overall Value of Learning Options for the transplant
program160
Health Care Reform and Access to Hematopoietic Cell
Transplantation
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The landmark health care reform bill, the Affordable Care
Act (ACA), was implemented on January 1, 2014. Among the
changes to the United State’s health care system are three
main aspects: 1) creation of health insurance exchanges, 2)
